Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?
JavaScript is disabled for your browser. Some features of this site may not work without it.
Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?
Gönczi, Lóránt; Végh, Zsuzsanna; Golovics, Petra Anna; Rutka, Mariann; Gecse, Krisztina; Bor, Renáta; Farkas, Klaudia; Szamosi, Tamás; Bene, László; Gasztonyi, Beáta; Kristóf, T; Lakatos, László; Miheller, Pál; Palatka, Károly; Papp, Mária; Patai, Árpád; Salamon, A; Tóth, GT; Vincze, Áron; Biró, Edina Márta; Lovász, Barbara Dorottya; Kürti, Zsuzsanna; Szepes, Zoltán; Molnár, Tamás; Lakatos, Péter László
Folyóiratcikk
JOURNAL OF CROHNS & COLITIS
vol.:11,
issue.:6,
p.:697-705.